香港六宝典
Company Profile

Established in 1999 in Shenzhen, China, LifeTech Scientific Corporation (Stock Code: 1302.HK) is committed to the R&D, manufacture, and sales of minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases. The Company provides patients with innovative solutions in the treatment of structural heart diseases, peripheral vascular diseases, and bradycardia, and the Company also expands its business scope in respiratory interventional business and neuro interventional business. Moreover, the Company has the world-first innovative iron-based bioabsorbable material technology platform. With the core strategy of innovation and internationalization, the market share of main products of the Company are keeping leading position in the home country, and the Company has established 7 subsidiaries outside mainland China, with network penetration in nearly 120 countries and regions around the world.

香港六宝典
香港六宝典
Our Business
香港六宝典

Structural Heart Business

Peripheral Vascular Business

Cardiac Pacing and Electrophysiology Business

Iron-based Bioabsorbable Material

Respiratory Interventional Business

Neurointerventional Business

Structural Heart Business
We provide structural heart disease patients with diversified minimally invasive interventional medical device solutions around the world. We have developed four generations of congenital heart disease occluders to catering different clinical needs, and we also developed technology-advanced left atrial appendage (LAA) closure systems, of which the LAmbre™ Plus LAA Closure System has been approved by the FDA to initiate an investigator-initiated pre-market clinical trial, and the trial has obtained medical insurance coverage in the United States. In addition, we are now actively developing interventional solutions for valvular diseases.
View Disease Solutions
Peripheral Vascular Business
We provide peripheral vascular disease patients with safe and effective endovascular solutions, striving to bring a comprehesive device treatment for patients around the world, including the treatment of aortic diseases, venous diseases, and arterial and venous embolizations.
View Disease Solutions
Cardiac Pacing and Electrophysiology Business
We leverage world-leading technology to bring domestic-made complete solutions to bradycardia patients in China with the world-class quality and competitive technology .
Iron-based Bioabsorbable Material
We develop the world’s unique iron-based bioabsorbable material technology through our subsidiary Biotyx Medical (Shenzhen) Co., Ltd. After nearly two decades of dedication to R&D, the first three core products for the treatment of coronary heart disease, pulmonary vascular stenosis and infrapopliteal artery stenosis, are currently at different phases of clinical trial. The usage of this novel iron-based bioabsorbable material will help to develop unprecedented, safe, and effective treatment options for patients around the world.
View Disease Solutions
Respiratory Interventional Business
We are committed to developing safe and effective interventional devices and solutions in the field of interventional pulmonology, and our novel devices are in different phases of R&D.
Neurointerventional Business
With the aim of satisfying unmet clinical needs and providing patients with next-generation neurointerventional solutions, we are delicated to develop interventional devices and solutions for neurological diseases. Currently, our novel products are in different phases of R&D.
Innovation for World Patients

We are continuously providing safe and effective innovative interventional medical device solutions for doctors and patients around the world, exerting every effort to promote our novel devices and advanced technology across the globe. 

  • 120 ~

    Countries and Regions Coverage

  • 970 +

    Distributors in World Market

  • 827

    Overseas Patents (Include Application)

  • 950 +

    Overseas Registration Certificates

Headquarters
Subsidiaries